---
document_datetime: 2025-09-30 16:22:56
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/deferasirox-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: deferasirox-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.1833404
conversion_datetime: 2025-12-28 11:57:48.139785
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Deferasirox Accord

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 30/09/2025                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000295785   | Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a (Type IB) - To update Section 4.2 of the SmPC to include information on posology based on the noninterventional study CICL670A2429. This was a survey to assess physicians' knowledge of the posology and biological monitoring recommendations as described in the Educational Materials of the reference product Exjade. The change follows assessment of the same change for the reference product Exjade. In addition, the MAH took the opportunity to implement editorial changes throughout the PI to align with the reference product and update the list of the local representatives in the PL.   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|